Covalent Ligands that Target the Human Papillomavirus E6 Oncoprotein
ChemBioChem · 12.11.2026 · 27 (21)
DOI: 10.1002/cbic.70590 ↗Kurz gefasst
Fachartikel in der Zeitschrift ChemBioChem, online erschienen am 05.11.2026. Verfasst von Charlotte M Zammit und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, University of California, Berkeley, Berkeley, California, USA. Hauptthemen laut MEDLINE: Oncogene Proteins, Viral, Repressor Proteins, Human Papillomavirus Viruses, Pyrazoles. Die Arbeit nennt 63 Literaturangaben. Gefördert von: National Institutes of Health (NIH), National Science Foundation (NSF), NIH HHS.
Abstract (Originalsprache)
The high‐risk human papillomavirus (HPV) early protein 6 (E6) viral oncoprotein is a key player in HPV‐mediated cancers and is the major driver of cervical, anal, and a substantial portion of head and neck cancers. HPV E6 recruits the cellular ubiquitin E3‐ligase E6‐associated protein (E6AP), also termed UBE3A, and this E6/E6AP complex in turn recruits the tumor suppressor p53, resulting in the ubiquitin‐mediated degradation of p53. The cysteine‐rich E6 protein presents an attractive target for chemical intervention through covalent, cysteine‐reactive chemistries. While previous studies have uncovered peptidic covalent inhibitors of E6, we sought to determine whether we could identify nonpeptidic functional binders. We screened a library of cysteine‐reactive covalent ligands and identified a pyrazoline hit, EN218, bearing a chloroacetamide cysteine‐reactive warhead. Evaluation of pyrazoline analogs led to the development of an improved molecule, ( S )‐WX48A, that stereoselectively reacted with C58 on E6 to inhibit E6‐mediated p53 ubiquitination. While this molecule is still in an early stage and requires further medicinal chemistry optimization to exert on‐target cellular activity, our study demonstrates that E6 can be directly and stereoselectively targeted with a covalent nonpeptidic small‐molecule and provides a foundation for developing more drug‐like E6 inhibitors for HPV therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Chemistry, University of California, Berkeley, Berkeley, California, USA.
- Department of Molecular and Cell Biology, University of California, Berkeley, Berkeley, California, USA.
- Innovative Genomics Institute, Berkeley, California, USA.
ORCID-Profile: Daniel K Nomura
Förderung
- National Institutes of Health (NIH)
- National Science Foundation (NSF)
- NIH HHS
- Directorate for Biological Sciences
Zitieren
APA
Zammit, C. M., & Nomura, D. K. (2026). Covalent Ligands that Target the Human Papillomavirus E6 Oncoprotein. ChemBioChem, 27(21). https://doi.org/10.1002/cbic.70590
Vancouver
Zammit CM, Nomura DK. Covalent Ligands that Target the Human Papillomavirus E6 Oncoprotein. ChemBioChem. 2026;27(21). doi:10.1002/cbic.70590
BibTeX
@article{Zammit2026,
author = {Zammit, Charlotte M and Nomura, Daniel K},
title = {Covalent Ligands that Target the Human Papillomavirus E6 Oncoprotein},
journal = {ChemBioChem},
year = {2026},
volume = {27},
number = {21},
doi = {10.1002/cbic.70590}
}
EUVIMED